Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment

Journal of the Neurological Sciences

Volumn 345, Issue 1, 2014, Pages 139-147

  Brown, Mark T ^a   Herrmann, David N ^b   Goldstein, Mark ^c   Burr, Aimee M ^a   Smith, Michael D ^a   West, Christine R ^a   Verburg, Kenneth M ^a   Dyck, Peter J ^d  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Medical Specialists of the Palm Beaches Inc ^*  (United States)

^d MAYO CLINIC   (United States)

Author keywords

Intraepidermal nerve fiber density; Nerve growth factor; Neurological safety; Osteoarthritis; Pain; limit 6 Tanezumab

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR;

ABNORMAL SENSATION; ADULT; ALLODYNIA; ANALGESIA; ANALGESIA (SENSORY DYSFUNCTION); ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DENSITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; EVIDENCE BASED PRACTICE; FAINTNESS; FALLING; FEMALE; FOOD AND DRUG ADMINISTRATION; FORMICATION; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; HYPERALGESIA; HYPERESTHESIA; HYPESTHESIA; HYPOREFLEXIA; INJECTION SITE BURNING; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INTRAEPIDERMAL NERVE FIBER DENSITY; JOINT SWELLING; LIMB PAIN; LOWER ABDOMINAL PAIN; LUMBAR SPINAL STENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA AND VOMITING; NECK PAIN; NERVE CONDUCTION; NERVOUS SYSTEM PARAMETERS; NEURALGIA; NEURITIS; NEUROLOGICAL COMPLICATION; OSTEOARTHRITIS; PERIPHERAL EDEMA; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PLACEBO EFFECT; POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCIATICA; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SYNOVIAL CYST; TENDINITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIBRATION SENSE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HEART RATE; MIDDLE AGED; NERVE FIBER; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS; NERVE GROWTH FACTOR; NEURAL CONDUCTION; PAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908209769     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.07.028     Document Type: Article

References (41)

1. R. Levi-Montalcini The nerve growth factor: thirty-five years later Biosci Rep 7 1987 681 699
2. C. Crowley, S.D. Spencer, M.C. Nishimura, K.S. Chen, S. Pitts-Meek, and M.P. Armanini Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons Cell 76 1994 1001 1011
3. P.W. Mantyh, M. Koltzenburg, L.M. Mendell, L. Tive, and D.L. Shelton Antagonism of nerve growth factor-TrkA signaling and the relief of pain Anesthesiology 115 2011 189 204
4. S.C. Apfel Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 50 2002 393 413
5. S.C. Apfel, S. Schwartz, B.T. Adornato, R. Freeman, V. Biton, and M. Rendell Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group JAMA 284 2000 2215 2221
6. P.J. Dyck, S. Peroutka, C. Rask, E. Burton, M.K. Baker, and K.A. Lehman Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans Neurology 48 1997 501 505
7. L. Aloe, M.A. Tuveri, U. Carcassi, and R. Levi-Montalcini Nerve growth factor in the synovial fluid of patients with chronic arthritis Arthritis Rheum 35 1992 351 355
8. D. Della Seta, L. de Acetis, L. Aloe, and E. Alleva NGF effects on hot plate behaviors in mice Pharmacol Biochem Behav 49 1994 701 705
9. D.A. Halliday, C. Zettler, R.A. Rush, R. Scicchitano, and J.D. McNeil Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease Neurochem Res 23 1998 919 922
10. F.F. Hefti, A. Rosenthal, P.A. Walicke, S. Wyatt, G. Vergara, and D.L. Shelton Novel class of pain drugs based on antagonism of NGF Trends Pharmacol Sci 27 2006 85 91
11. G.R. Lewin, A. Rueff, and L.M. Mendell Peripheral and central mechanisms of NGF-induced hyperalgesia Eur J Neurosci 6 1994 1903 1912
12. E.M. Lowe, P. Anand, G. Terenghi, R.E. Williams-Chestnut, D.V. Sinicropi, and J.L. Osborne Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis Br J Urol 79 1997 572 577
13. J.C. McArthur, C. Yiannoutsos, D.M. Simpson, B.T. Adornato, E.J. Singer, and H. Hollander A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291 Neurology 54 2000 1080 1088
14. L.J. Miller, K.A. Fischer, S.J. Goralnick, M. Litt, J.A. Burleson, and P. Albertsen Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome Urology 59 2002 603 608
15. D. Oddiah, P. Anand, S.B. McMahon, and M. Rattray Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder Neuroreport 9 1998 1455 1458
16. P. Sarchielli, A. Alberti, A. Floridi, and V. Gallai Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients Neurology 57 2001 132 134
17. C.J. Woolf, B. Safieh-Garabedian, Q.P. Ma, P. Crilly, and J. Winter Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity Neuroscience 62 1994 327 331
18. Y.N. Abdiche, D.S. Malashock, and J. Pons Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci 17 2008 1326 1335
19. Bramson C, Herrmann D, Biton V, Carey W, Keller D, Brown M, et al. Efficacy and safety of subcutaneous tanezumab in patients with pain related to diabetic peripheral neuropathy (NCT01087203). 32nd Annual Scientific Meeting of the American Pain Society (APS). New Orleans, LA.
20. M.T. Brown, F.T. Murphy, D.M. Radin, I. Davignon, M.D. Smith, and C.R. West Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial J Pain 13 2012 790 798
21. M.T. Brown, F.T. Murphy, D.M. Radin, I. Davignon, M.D. Smith, and C.R. West Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase 3 trial Arthritis Rheum 65 2013 1795 1803
22. Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab in osteoarthritis hip and knee pain: comparison to placebo and naproxen in two phase III studies (NCT00830063 & NCT00863304). American Pain Society (APS) 30th Annual Scientific Meeting. Austin, TX.
23. R.J. Evans, R.M. Moldwin, N. Cossons, A. Darekar, I.W. Mills, and D. Scholfield Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis J Urol 185 2011 1716 1721
24. N. Katz, D.G. Borenstein, C. Birbara, C. Bramson, M.A. Nemeth, and M.D. Smith Efficacy and safety of tanezumab in the treatment of chronic low back pain Pain 152 2011 2248 2258
25. A.J. Kivitz, J.S. Gimbel, C. Bramson, M.A. Nemeth, D.S. Keller, and M.T. Brown Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain Pain 154 2013 1009 1021
26. N.E. Lane, T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, and M.D. Smith Tanezumab for treatment of knee osteoarthritis pain N Engl J Med 363 2010 1521 1531
27. H. Nagashima, M. Suzuki, S. Araki, T. Yamabe, and C. Muto Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study Osteoarthritis Cartilage 19 2011 1405 1412
28. T.J. Schnitzer, N.E. Lane, C. Birbara, M.D. Smith, S.L. Simpson, and M.T. Brown Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain Osteoarthritis Cartilage 19 2011 639 646
29. Yazici Y, Ekman EF, Greenberg HS, Smith MD, Brown MT, West CR, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354). American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting. Chicago, IL.
30. P.J. Dyck, J.E. Norell, H. Tritschler, K. Schuette, R. Samigullin, and D. Ziegler Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity Diabetes Care 30 2007 2619 2625
31. P.J. Dyck, J.L. Davies, W.J. Litchy, and P.C. O'Brien Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort Neurology 49 1997 229 239
32. R. Altman, G. Alarcon, D. Appelrouth, D. Bloch, D. Borenstein, and K. Brandt The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip Arthritis Rheum 34 1991 505 514
33. R. Altman, E. Asch, D. Bloch, G. Bole, D. Borenstein, and K. Brandt Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Arthritis Rheum 29 1986 1039 1049
34. J.H. Kellgren, and J.S. Lawrence Radiological assessment of osteo-arthrosis Ann Rheum Dis 16 1957 494 502
35. G. Lauria, D.R. Cornblath, O. Johansson, J.C. McArthur, S.I. Mellgren, and M. Nolano EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy Eur J Neurol 12 2005 747 758
36. R. Schiffmann, P. Hauer, B. Freeman, M. Ries, L.J. Scott, and M. Polydefkis Enzyme replacement therapy and intraepidermal innervation density in Fabry disease Muscle Nerve 34 2006 53 56
37. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
38. K. Stengaard-Pedersen, R. Ekesbo, A.L. Karvonen, and M. Lyster Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing Rheumatology (Oxford) 43 2004 592 595
39. P.J. Dyck, R.A. Hughes, and P. O'Brien Quantitating overall neuropathic symptoms, impairments and outcomes P.J. Dyck, P.K. Thomas, Peripheral neuropathy 4th ed. 2005 Elsevier Philadelphia 1031 1051
40. J.C. Nickel, G. Atkinson, J.N. Krieger, I.W. Mills, M. Pontari, and D.A. Shoskes Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome Urology 80 2012 1105 1110
41. G.L. Pittenger, M. Ray, N.I. Burcus, P. McNulty, B. Basta, and A.I. Vinik Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients Diabetes Care 27 2004 1974 1979